Diabetes Obes Metab: The effects of liraglutide on diet, appetite and eating behavior of overweight type 1 diabetics

A recent study published in the journal Diabetes Obesity and Metabolism, an authoritative journal in the field of metabolic endocrine diseases, looked at the effects of adding liraglutide to a basic/high-dose insulin treatment for 24 weeks on diet, appetite and eating behavior in overweight/obese type 1 diabeticsIn a double-blind cross-examination study, 15 participants were randomly assigned (1:1) to be given a placebo or liraglutide treatment for 24 weeks, including 1 month of drops regularly, at doses from 0.6 mg to 1.2 mg, to 1.8 mg, in addition to insulinAfter treatment, a 1-month period of elutionThe participants were then assigned to another group for a further 24 weeks of treatmentThe researchers measured the subjects' food intakeThe subjects completed a visual simulation scale and a three-factor diet questionnaireThe researchers used a double-rank test to compare the parameterswhen using liraglutide, subjects changed their random food intake by reducing their total intake and fat percentage, as well as increasing carbohydratesTheir appetite seamounts: a desire to eat on an empty stomach, a significant reduction in hunger and expected food intakeAfter a standard breakfast, the feeling of satiety will be extended for several hoursIn this randomized clinical trial, overweight/obese type 1 diabetes patients significantly improved their food intake, appetite and eating behavior after 24 weeks of adding liraglutide to the basic/high-dose insulin treatment